A Phase 1 interventional study of Zanubrutinib and Obinutuzumab in B-cell Lymphoid Malignancies, sponsored by BeiGene. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Lymphoma with a site in Australia — 24 open to participants now, 40 under way, 15 of them phase 3. Lymphoma · Australia.
Among the 120 studies in Lymphoma with a site in Australia, this one is the 63rd largest by enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2016, is one of 24 in phase 1, and was the 63rd registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →24 of the 120 studies in Lymphoma with a site in Australia are open now. Recruiting first, the newest first:
Arovella Therapeutics Ltd · Sites in Australia
Ages 18+
AstraZeneca · Sites in Australia, United States, Canada and 2 more countries
Ages 18–18
ModeX Therapeutics, An OPKO Health Company · Sites in Australia, Israel, Spain
Ages 18+
Lyell Immunopharma, Inc. · Sites in Australia, United States, Canada
Ages 18+
Treeline Biosciences, Inc. · Sites in Australia, United States, Canada
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 56 · Phase 3 44
First in 1994; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 132 across the 116 interventional studies, 420 across the 1 observational. Of the 77 that completed or were terminated, 30 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 120 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 6 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphoma with a site in Australia that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT07202078Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | 2027-03-31 |
| NCT07202052Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | 2027-03-31 |
| NCT07202091Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | 2027-03-31 |
| NCT07202065Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | 2027-03-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies in Lymphoma with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Laboratory parameters as specified below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the dose-escalation part, dose levels and regimens were evaluated. In the indication-specific expansion cohorts, participants were assigned to different cohorts based on histology type.
Drug: Zanubrutinib · Drug: Obinutuzumab
Also known as: BGB-3111
Part 1 : Number Of Participants Experiencing Adverse Events
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A serious AE (SAE) was any untoward medical occurrence that, at any dose. * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1: Number Of Participants With Clinical Laboratory Abnormalities
Laboratory results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.
Time frame: Day -28 to -1 (predose) through 4 years and 8 months
Part 1: Number Of Deaths
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)
Dose-limiting toxicities were defined as a toxicity or AE occurring during the DLT assessment period (first 29 days of treatment), which is not clearly attributable to a cause other than zanubrutinib and/or obinutuzumab (such as disease progression, underlying illness, concurrent illness or concomitant medication) and meets one of the following criteria: * Grade 3 or 4 drug-related non-hematologic toxicity (excluding Grade 3 nausea, vomiting, hypertension, and asymptomatic laboratory abnormalities), * Grade 4 drug-related hematologic toxicity persisting for \>14 days, * any grade toxicity, which in the judgment of the investigator or Sponsor, required removal of the participant from the study.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response
Partial response was defined as follows: * ≥ 50% reduction of serum IgM from baseline, * reduction in lymphadenopathy/splenomegaly (if present at baseline). For response assessments that occurred during cycles where a CT scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response
Complete response was defined as follows: * normal serum IgM values, * disappearance of monoclonal protein by immunofixation, * no histological evidence of bone marrow involvement, * complete resolution of lymphadenopathy/splenomegaly (if present at baseline) For response assessments that occurred during cycles where a computed tomography (CT) scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Progression-free Survival (PFS)
Progression-free survival was defined as time (in months) from the start of treatment with zanubrutinib or obinutuzumab to the first documented disease progression or death due to any cause, whichever occurred first. Results are reported as the median months for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL).
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Duration Of Response (DOR)
Duration of response for responders was defined as the time (in months) from the date of the earliest qualifying response to the date of progressive disease or death due to any cause (whichever occurred earlier). Duration of response was analyzed using the same methods as the analysis for PFS. Responses after initiating new anticancer therapy, roll over to the long-term extension (LTE) study, or the first occurrence of disease progression were not considered in the analysis.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Time To Response (TTR)
The TTR for responders was defined as time (in months) from the start of the study treatment to the date of the earliest qualifying response. The TTR was summarized using descriptive statistics. Responses after initiating new anticancer therapy, roll over to the LTE study, or the first occurrence of disease progression were not considered in the analysis of TTR.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Overall Survival (OS)
Overall survival was defined as the time (in months) from the date of the start of the study treatment to death due to any cause. Participants who were alive before final database lock or discontinuation of the study (discontinued study due to reasons other than death) were censored at their last known alive date on or before database lock.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1 and Part 2: Hematologic Improvement In Participants With CLL
The number and percentage of participants with CLL with anemia (hemoglobin ≤110 grams/liter \[g/L\]), neutropenia (absolute neutrophil count ≤1.5 x 10\^9/L), or thrombocytopenia (platelet count ≤100 x 10\^9/L) at baseline were estimated.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUClast) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To Infinity Time (AUC) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1: Maximum Plasma Concentration (Cmax) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1: Time To Maximum Plasma Concentration (Tmax) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1: Terminal Elimination Half-life (t1/2) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1: Apparent Clearance (CL/F) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1: Apparent Volume Of Distribution (Vz/F) Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1 and Part 2: Steady State AUClast Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1 and Part 2: Steady State Cmax of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 1 and Part 2: Steady State Tmax Of Zanubrutinib
Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Part 2: Number Of Participants Experiencing Adverse Events
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
Time frame: Day 1 (first dose) through 4 years and 8 months
Part 2: Number Of Participants With Clinical Laboratory Abnormalities
Results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.
Time frame: Day -28 to -1 (predose) through 4 years and 8 months
Part 2: Number Of Deaths
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * is life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
Time frame: Day 1 (first dose) through 4 years and 8 months
This study was conducted at 15 study centers in Australia, South Korea, and the United States (US). A total of 119 participants were enrolled in the study and received ≥1 dose of study treatment.
| Milestone | Zanubrutinib and Obinutuzumab |
|---|---|
| Started | 119 |
| Completed | 0 |
| Not completed | 119 |
| Withdrew: Roll over to long-term extension study | 73 |
| Withdrew: Death | 33 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Progressive disease at study withdrawal and death by end of study | 1 |
| Withdrew: Palliative care | 1 |
| Withdrew: Transitioned to long term follow up study | 1 |
| Withdrew: Transitioned to long term extension study | 1 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A serious AE (SAE) was any untoward medical occurrence that, at any dose. * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
| Participants | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| Any TEAE | 12 |
| SAE | 7 |
Laboratory results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.
| Participants | Part 1: 160 mg BID | Part 1: 320 mg QD |
|---|---|---|
| Leukocytes: Low Directionality | 1 | 0 |
| Lymphocytes: Low Directionality | 1 | 3 |
| Lymphocytes: High Directionality | 1 | 1 |
| Neutrophils: Low Directionality | 1 | 3 |
| Platelets: Low Directionality | 0 | 1 |
| Phosphate: Low Directionality | 1 | 0 |
| Urate: High Directionality | 0 | 1 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
| Participants | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| Part 1: Number Of Deaths | 0 |
Dose-limiting toxicities were defined as a toxicity or AE occurring during the DLT assessment period (first 29 days of treatment), which is not clearly attributable to a cause other than zanubrutinib and/or obinutuzumab (such as disease progression, underlying illness, concurrent illness or concomitant medication) and meets one of the following criteria: * Grade 3 or 4 drug-related non-hematologic toxicity (excluding Grade 3 nausea, vomiting, hypertension, and asymptomatic laboratory abnormalities), * Grade 4 drug-related hematologic toxicity persisting for \>14 days, * any grade toxicity, which in the judgment of the investigator or Sponsor, required removal of the participant from the study.
| Participants | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| Part 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT) | 0 |
Partial response was defined as follows: * ≥ 50% reduction of serum IgM from baseline, * reduction in lymphadenopathy/splenomegaly (if present at baseline). For response assessments that occurred during cycles where a CT scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.
| Participants | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response | 51 |
Complete response was defined as follows: * normal serum IgM values, * disappearance of monoclonal protein by immunofixation, * no histological evidence of bone marrow involvement, * complete resolution of lymphadenopathy/splenomegaly (if present at baseline) For response assessments that occurred during cycles where a computed tomography (CT) scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.
| Participants | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response | 36 |
Progression-free survival was defined as time (in months) from the start of treatment with zanubrutinib or obinutuzumab to the first documented disease progression or death due to any cause, whichever occurred first. Results are reported as the median months for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL).
| Months | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| WM | 37.13 (6.31 to NA) |
| FL | 24.87 (11.07 to NA) |
| MZL | 40.25 (8.25 to NA) |
| Non-GCB DLBCL | 2.86 (1.71 to 7.39) |
| Total | 40.25 (27.63 to NA) |
| CLL/SLL | NA (44.48 to NA) |
Duration of response for responders was defined as the time (in months) from the date of the earliest qualifying response to the date of progressive disease or death due to any cause (whichever occurred earlier). Duration of response was analyzed using the same methods as the analysis for PFS. Responses after initiating new anticancer therapy, roll over to the long-term extension (LTE) study, or the first occurrence of disease progression were not considered in the analysis.
| Months | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| WM | 35.84 (21.03 to NA) |
| FL | 39.75 (18.63 to NA) |
| Non-GCB DLBCL | 12.75 (2.89 to NA) |
| CLL/SLL | NA (42.02 to NA) |
| MCL | NA (2.73 to NA) |
| MZL | NA (31.80 to NA) |
The TTR for responders was defined as time (in months) from the start of the study treatment to the date of the earliest qualifying response. The TTR was summarized using descriptive statistics. Responses after initiating new anticancer therapy, roll over to the LTE study, or the first occurrence of disease progression were not considered in the analysis of TTR.
| Months | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| CLL/SLL | 3.14 ± 1.551 |
| WM | 2.81 ± 0.050 |
| FL | 3.32 ± 1.511 |
| MCL | 2.77 ± 0.157 |
| MZL | 5.62 ± 4.042 |
| Non-GCB DLBCL | 2.76 ± 0.297 |
| Total | 3.18 ± 1.487 |
Overall survival was defined as the time (in months) from the date of the start of the study treatment to death due to any cause. Participants who were alive before final database lock or discontinuation of the study (discontinued study due to reasons other than death) were censored at their last known alive date on or before database lock.
| Months | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| Non-GCB DLBCL | 11.93 (3.52 to 16.53) |
| CLL/SLL | NA (NA to NA) |
| WM | NA (22.4 to NA) |
| FL | NA (42.45 to NA) |
| MCL | NA (7.92 to NA) |
| MZL | NA (NA to NA) |
The number and percentage of participants with CLL with anemia (hemoglobin ≤110 grams/liter \[g/L\]), neutropenia (absolute neutrophil count ≤1.5 x 10\^9/L), or thrombocytopenia (platelet count ≤100 x 10\^9/L) at baseline were estimated.
| Participants | Zanubrutinib and Obinutuzumab |
|---|---|
| Participants with anemia at baseline who had normalized hemoglobin after treatment | 11 |
| Participants with neutropenia at baseline who had normalized hemoglobin after treatment | 3 |
| Participants with thrombocytopenia at baseline who had normalized hemoglobin after treatment | 12 |
| nanogram/milliliter*hour | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 1123.59 ± 71.482 |
| 320 mg QD | 2179.54 ± 70.237 |
| nanogram/milliliter*hour | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 1324.63 ± 60.981 |
| 320 mg QD | 3052.47 ± 33.681 |
| nanogram/milliliter | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 360.42 ± 90.350 |
| 320 mg QD | 589.37 ± 79.884 |
| hour | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 1.60 ± 38.285 |
| 320 mg QD | 1.73 ± 88.663 |
| hour | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 1.88 ± 29.532 |
| 320 mg QD | 1.79 ± 19.945 |
| milliliter/hour | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 120789.1 ± 60.965 |
| 320 mg QD | 104832.9 ± 33.681 |
| milliliter | Part 1: Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 327343.8 ± 97.981 |
| 320 mg QD | 270810 ± 36.099 |
| nanogram/milliliter*hour | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 1074.1 ± 42.1 |
| 320 mg QD | 2003.9 ± 42.6 |
| nanogram/milliliter | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 328.5 ± 52.3 |
| 320 mg QD | 580 ± 42.6 |
| hour | Zanubrutinib and Obinutuzumab |
|---|---|
| 160 mg BID | 1.8 ± 67.0 |
| 320 mg QD | 1.9 ± 48.4 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
| Participants | Part 2: Zanubrutinib and Obinutuzumab |
|---|---|
| Any AE | 119 |
| SAE | 62 |
Results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.
| Participants | Part 2: 160 mg BID |
|---|---|
| Hemoglobin: Low Directionality | 3 |
| Leukocytes: Low Directionality | 7 |
| Leukocytes: High Directionality | 0 |
| Lymphocytes: Low Directionality | 10 |
| Lymphocytes: High Directionality | 2 |
| Neutrophils: Low Directionality | 11 |
| Platelets: Low Directionality | 7 |
| Alanine Aminotransferase: High Directionality | 1 |
| Albumin: Low Directionality | 5 |
| Alkaline Phosphatase: High Directionality | 1 |
| Aspartate Aminotransferase: High Directionality | 1 |
| Glucose: High Directionality | 3 |
| Phosphate: Low Directionality | 3 |
| Sodium: Low Directionality | 1 |
| Urate: High Directionality | 1 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * is life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.
| Participants | Part 2: Zanubrutinib and Obinutuzumab |
|---|---|
| Total deaths | 34 |
| Progression of disease | 24 |
| Unknown | 2 |
| Acute respiratory distress syndrome | 1 |
| Road traffic accident | 1 |
| Bone marrow failure and metastatic skin squamous cell carcinoma | 1 |
| Cardiac arrest during admission to private hospital for bowel resection for colorectal cancer | 1 |
| Chest infection | 1 |
| CLL/sepsis | 1 |
| Metastatic breast cancer | 1 |
| Undisclosed | 1 |
Collected over Day 1 (first dose) through 4 years and 8 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib and Obinutuzumab | 34/119 (28.6%) | 62/119 (52.1%) | 119/119 (100%) |
| Event | Zanubrutinib and Obinutuzumab |
|---|---|
| PneumoniaInfections and infestations | 8/119 |
| PyrexiaGeneral disorders | 8/119 |
| NeutropeniaBlood and lymphatic system disorders | 5/119 |
| InfluenzaInfections and infestations | 4/119 |
| Urinary tract infectionInfections and infestations | 4/119 |
| CellulitisInfections and infestations | 3/119 |
| GastroenteritisInfections and infestations | 3/119 |
| SepsisInfections and infestations | 3/119 |
| Abdominal painGastrointestinal disorders | 3/119 |
| AppendicitisInfections and infestations | 2/119 |
| Event | Zanubrutinib and Obinutuzumab |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 55/119 |
| NeutropeniaBlood and lymphatic system disorders | 41/119 |
| ContusionInjury, poisoning and procedural complications | 39/119 |
| FatigueGeneral disorders | 38/119 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/119 |
| DiarrhoeaGastrointestinal disorders | 31/119 |
| ThrombocytopeniaBlood and lymphatic system disorders | 26/119 |
| RashSkin and subcutaneous tissue disorders | 23/119 |
| NauseaGastrointestinal disorders | 22/119 |
| PetechiaeSkin and subcutaneous tissue disorders | 18/119 |
| Age, Continuous(years) | Zanubrutinib and Obinutuzumab |
|---|---|
| Median | 68 (34 to 86) |
| Sex: Female, Male(Participants) | Zanubrutinib and Obinutuzumab |
|---|---|
| Female | 41 |
| Male | 78 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib and Obinutuzumab |
|---|---|
| White | 107 |
| Black or African American | 1 |
| Asian | 11 |
| Not Hispanic or Latino | 117 |
| Hispanic or Latino | 2 |
| Vital Signs(millimeters of mercury) | Zanubrutinib and Obinutuzumab |
|---|---|
| Blood Pressure (Systolic) | 124.5 ± 17.75 |
| Blood Pressure (Diastolic) | 71.5 ± 11.46 |
| Pulse Rate(beats/minute) | Zanubrutinib and Obinutuzumab |
|---|---|
| Mean | 78.2 ± 13.86 |
| Weight(kilograms) | Zanubrutinib and Obinutuzumab |
|---|---|
| Mean | 78.95 ± 18.004 |
| Height(centimeters) | Zanubrutinib and Obinutuzumab |
|---|---|
| Mean | 170.92 ± 9.382 |
| Body Mass Index(kilograms/squared meter) | Zanubrutinib and Obinutuzumab |
|---|---|
| Mean | 26.876 ± 4.9513 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jan 2016 to primary completion in Sep 2020, 55 months.
Results were first posted in Nov 2021, 1 year 2 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 55 months is above that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib